Early laparoscopic Nissen fundoplication for recurrent reflux esophagitis: a cost-effective alternative to omeprazole
- PMID: 10444007
- PMCID: PMC3015328
Early laparoscopic Nissen fundoplication for recurrent reflux esophagitis: a cost-effective alternative to omeprazole
Abstract
Background: Eighty percent of patients treated medically for gastroesophageal reflux disease relapse after treatment. Many of these patients require indefinite treatment with omeprazole to prevent recurrence. Nissen fundoplication has been shown to be effective, safe and cost effective in the management of gastroesophageal reflux disease. We suggest a treatment algorithm, which encourages early surgical intervention in cases of recurrent esophagitis after a previously successful two-month course of omeprazole.
Methods: We have offered laparoscopic Nissen fundoplication since 1993. Patients who received Nissen fundoplication since 1990 were asked to report return to baseline activity, medications, and lifestyle changes. Concurrent chart review of patients treated with omeprazole was conducted to analyze cost.
Results: Patients receiving laparoscopic Nissen fundoplication were discharged significantly sooner and spent significantly less time convalescing when compared to those who underwent open Nissen fundoplication. Laparoscopic Nissen fundoplication became cost effective at 1.5 to 2 years when compared to omeprazole.
Conclusion: Based on cost analysis, patient satisfaction, acceptable complication rate, and efficient use of time and resources, we recommend laparoscopic Nissen fundoplication as the appropriate treatment in patients who develop recurrent esophagitis after a two-month treatment with omeprazole.
Figures
References
-
- Richter JE, Bradley LA, Castell DO. Esophageal chest pain: current controversies in pathogenesis, diagnosis, and therapy. Ann Intern Med. 1989;110:66–78 - PubMed
-
- Spechler SJ. Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease. N Engl J Med. 1992;326:825–827 - PubMed
-
- Klinkenburg-Knoll EC, Meuwissen SM. Medical therapy of patients with reflux esophagitis poorly responsive to H-2 receptor antagonist therapy. Digestion. 1992:51(Suppl 1):44–48 - PubMed
-
- Laursen B, Bonesen J, Hansen J, et al. Omeprazole 10 mg or 20 mg daily for the prevention of relapse in gastroesophageal reflux disease? A double blind comparative study (Abstract). Gastroentero. 1992;102:A109
-
- Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic ulcer esophagitis after treatment with omeprazole. Gastroentero. 1988;95:902–912 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources